Rgenta Therapeutics Presents Preclinical Data from Lead Program RGT-61159, a Potent Inhibitor of Oncogenic MYB Synthesis, at the American Society of Clinical Oncology Annual Meeting (ASCO 2024)

Posted on by

Orally available RGT-61159 demonstrates potent inhibition of MYB synthesis and significant anti-tumor activity in a range of xenograft models of adenoid cystic carcinoma (ACC) Data support planned first-in-human Phase 1 clinical trial of RGT-61159 in both ACC and colorectal cancer (CRC)…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.